Deep Dive
Industry insights from our journalists
-
Why payers are gobbling up PBMs
On Monday the Justice Department gave its blessing to a $67 billion acquisition of Express Scripts by Cigna.
Samantha Liss • Sept. 18, 2018 -
FDA confronts its limits in push on drug pricing
Legally, regulating prices is outside of the FDA's purview. But that hasn't stopped Scott Gottlieb from taking a more vocal approach to the hot-button issue than past FDA chiefs.
Ned Pagliarulo • Aug. 27, 2018 -
FDA ups the ante for copycats, antibiotics, orphan drugs. But is it working?
Regulators are using incentives to spur development of much-needed drugs. The results so far have been mixed.
Jacob Bell • Aug. 27, 2018 -
How Scott Gottlieb is upending FDA communication, one tweet at a time
The FDA commissioner has relentlessly pumped out tweets, statements and more. But how has that affected FDA communications and the agency overall?
Andrew Dunn • Aug. 27, 2018 -
5 takeaways from payer Q2 earnings reports
Health insurers found success in Medicare, Medicaid and even the ACA exchanges.
Les Masterson • Aug. 08, 2018 -
3 blockchain applications to watch in logistics
Complex supply chains make the logistics industry a prime proving ground for blockchain — a technology that could also be useful for pharmaceuticals.
Deborah Abrams Kaplan • July 30, 2018 -
Seeking to adopt AI, drugmakers search for right mix of talent
AI holds promise as a powerful new tool in the hunt for new drugs. Yet building a team that blends tried-and-true methods with AI remains a challenge.
Ned Pagliarulo • July 23, 2018 -
Pharma and AI? Let's try augmented intelligence first
Both collaborations and in-house capabilities will likely be needed for pharma to successfully use AI across drug development.
Lisa LaMotta • July 23, 2018 -
Payers, doctors weigh AI's disruptive prescribing potential
The disruption won't happen overnight, though, as big tech firms try to not only develop healthcare AI tools, but show they'll enhance, rather than upend, the doctor-patient relationship.
Jacob Bell • July 23, 2018 -
Immunotherapy advances spur new look at cancer vaccines
Researchers have long been intrigued by the idea of a cancer vaccine, drawn in by hints of an immune role in cases of "spontaneous" remissions to cancer. Now, the immunotherapy boom is opening up new areas of research.
Ned Pagliarulo • June 25, 2018 -
Why be a vaccine company?
Lower margins and pricey manufacturing are hallmarks of vaccine making. Yet the drugs can provide a steady, and often competition-free, source of revenue.
Jacob Bell • June 25, 2018 -
Garabedian has few regrets and is ready to be seen
The former embattled Sarepta CEO is attempting a comeback by exploring a different facet of an industry he knows well.
Lisa LaMotta • June 11, 2018 -
What you need to know about NASH
BioPharma Dive is taking a deeper look at how this market is changing, the challenges drugmakers will face if they reach commercialization and the shifting market sentiment.
Lisa LaMotta • May 31, 2018 -
Pharma turn to NASH unlikely to mirror meteoric rise of hep C
Hopes of a hepatitis C-sized market could be dashed by the complexity of and challenges in diagnosing the lesser-known liver disease.
Ned Pagliarulo • May 21, 2018 -
After a flurry, NASH deals put on pause
After several years of dealmaking in the liver disease space, the industry waits for the next wave of assets to mature.
Lisa LaMotta • May 21, 2018 -
NASH drug pipeline headed toward uncertain market
The fatty liver disease has dozens of treatments in the global pipeline. But investors are treading lightly, casting doubt on the market opportunity.
Jacob Bell • May 21, 2018 -
3 market-busting hurdles to NASH commercialization
With the first NASH drugs expected to win approval over the next two to three years, drugmakers will face several major barriers to market entry.
Lisa LaMotta • May 21, 2018 -
Oncology boom spurs DTC advertising, and with it controversy
As the debate for and against direct-to-consumer advertising rages on, cancer drugmakers look poised to pump massive amounts of money into the practice.
Jacob Bell • May 16, 2018 -
Pharma breathes easy as Trump's drug pricing plan fizzles
While Trump vowed to bring drug prices down, pharma and biotech stocks jumped higher after his speech delivered few immediate actions.
David Lim • May 11, 2018 -
What to expect from Trump's Friday drug pricing speech
The president is expected to lay out his administration's latest slate of proposals aimed at lowering the cost of drugs.
David Lim • May 10, 2018 -
The pharma supply chain: What you need to know
Drug development is no easy feat. But even when manufacturing is perfected, getting treatments from plants to patients remains a hurdle.
Jacob Bell • April 24, 2018 -
Lilly's JAK woes set the stage for AbbVie, Gilead to jump ahead
An adcomm's iffy stance on baricitinib could mean one less thing to worry about for rivals looking to break into the fairly open JAK inhibitor market.
Jacob Bell • April 24, 2018 -
Pharma supply chains could use a tech reboot
While more prosaic than drug R&D, supply chains are increasingly important as the industry moves toward personalized medicine.
Kate Patrick • April 23, 2018 -
The Drug Supply Chain Security Act: A progress report
Five years in and one enforcement extension later, pharmaceutical companies still have a long way to go to fulfill the goal of true traceability.
Edwin Lopez • April 23, 2018 -
As India, China drug industries mature, FDA scrutiny an overhang
Rising numbers of warning letters have put production quality in focus, just as both countries turn further toward novel drug R&D.
Ned Pagliarulo • April 23, 2018